Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide receptor–targeting ⁶⁸Ga-RM2 with the prostate-specific membrane antigen (PSMA)–targeting ⁶⁸Ga-PSMA11 and ¹⁸F-DCFPyL. Methods: Fifty patients underwent both ⁶⁸Ga-RM2 PET/MRI and ⁶⁸Ga-PSMA11 (n = 23) or ¹⁸F-DCFPyL (n = 27) PET/CT at an interval ranging from 1 to 60 d (mean ± SD, 15.8 ± 17.7 d). SUV_max was collected for all lesions. Results: ⁶⁸Ga-RM2 PET was positive in 35 and negative in 15 of the 50 patients. ⁶⁸Ga-PSMA11/¹⁸F-DCFPyL PET was positive in 37 and negative in 13 of the 50 patients. Both scans detected 70 lesions in 32 patients. Forty-three lesions in 18 patients were identified on only 1 scan: ⁶⁸Ga-RM2 detected 7 more lesions in 4 patients, whereas ⁶⁸Ga-PSMA11/¹⁸F-DCFPyL detected 36 more lesions in 13 patients. Conclusion: ⁶⁸Ga-RM2 remains a valuable radiopharmaceutical even when compared with the more widely used ⁶⁸Ga-PSMA11/¹⁸F-DCFPyL in the evaluation of BCR of PC. Larger studies are needed to verify that identifying patients for whom these 2 classes of radiopharmaceuticals are complementary may ultimately allow for personalized medicine.

正在评估用于 PET 的新型放射性药物对前列腺癌 (PC) 生化复发 (BCR) 的诊断。我们比较了靶向⁶⁸ Ga-RM2 的胃泌素释放肽受体与靶向⁶⁸ Ga-PSMA11 和¹⁸ F-DCFPyL 的前列腺特异性膜抗原 (PSMA)。方法： 50 名患者接受了⁶⁸ Ga-RM2 PET/MRI 和⁶⁸ Ga-PSMA11 ( n = 23) 或¹⁸ F-DCFPyL ( n = 27) PET/CT，间隔时间为 1 至 60 天（平均值±SD， 15.8±17.7d)。收集所有病变的 SUV _max 。结果： 50 名患者中， ⁶⁸ Ga-RM2 PET 检测结果为 35 例阳性，15 例阴性。 50 名患者中，37 名患者的⁶⁸ Ga-PSMA11/ ¹⁸ F-DCFPyL PET 呈阳性，13 名呈阴性。两次扫描均检测到 32 名患者的 70 个病变。仅在 1 次扫描中就识别出了 18 名患者的 43 个病变： ⁶⁸ Ga-RM2 在 4 名患者中检测到了 7 个以上病变，而⁶⁸ Ga-PSMA11/ ¹⁸ F-DCFPyL 在 13 名患者中检测到了 36 个以上病变。结论：即使与评估 PC BCR 时更广泛使用的⁶⁸ Ga-PSMA11/ ¹⁸ F-DCFPyL 相比， ⁶⁸ Ga-RM2 仍然是一种有价值的放射性药物。需要更大规模的研究来验证，识别出这两类放射性药物互补的患者可能最终可以实现个性化医疗。